MedPath

The Effects of Wild Blueberries on Depressive Symptoms in Young Adults

Not Applicable
Completed
Conditions
Anhedonia
Depression
Anxiety
Interventions
Dietary Supplement: Wild blueberry powder
Dietary Supplement: Placebo powder
Registration Number
NCT04647019
Lead Sponsor
University of Reading
Brief Summary

This study aims to investigate the effects of a 6-week dietary intervention of 22 g freeze-dried whole wild blueberry powder. The outcomes include measures of depression, anxiety, anhedonia, cognitive function, and biomarkers of inflammation and oxidative stress.

Detailed Description

A randomized, double-blind, placebo-controlled, parallel-design study assessing the effects of a 6-week intervention of wild blueberry powder in young adults with depressive symptoms. A total of 60 participants will be randomly assigned to either 22 g blueberry powder or a matched placebo powder consumed daily with water. The severity of depression, anxiety, anhedonia, perceived stress, and quality of life will be measured at baseline and 6 weeks later. In addition, we will assess changes in cognitive function and transient mood 2 hours after consuming a single dose of blueberries.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
62
Inclusion Criteria
  • 18 to 24 years of age
  • Patient Health Questionnaire-9 score ≥ 10 and a score ≥ 2 on the sum of items 1 and 2
  • Willingness to provide blood samples
Exclusion Criteria
  • Any medically significant condition (e.g. diabetes, endocrine or gastrointestinal disorders)
  • Taking medication (excluding hormonal contraception)
  • History of mental illness (excluding anxiety and unipolar depressive disorders)
  • Allergy to blueberries or any other Vaccinium species
  • Receiving psychotherapy or counselling

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Blueberry powderWild blueberry powder-
Placebo powderPlacebo powder-
Primary Outcome Measures
NameTimeMethod
Beck Depression Inventory-II (BDI-II)6 weeks

A validated 21-item self-rated scale for assessing depression severity. The scale ranges from 0 to 63 points with higher scores indicating more severe depressive symptomatology.

Secondary Outcome Measures
NameTimeMethod
Snaith-Hamilton Pleasure Scale (SHAPS) - modified version6 weeks

A 14-item self-rated scale for measuring anhedonia. Each item has been modified to have five possible responses, which are scored as follows: "strongly disagree" (4 points), "somewhat disagree" (3 points), "neither agree nor disagree" (2 points), "somewhat agree" (1 point), "strongly agree" (0 points). Thus, the scale will range from 0 to 56 points with higher scores indicating greater levels of anhedonia.

Brain-derived neutrophic factor (BDNF) in serum6 weeks

Serum levels of BDNF will be analyzed using enzyme-linked immunosorbent assay (ELISA).

Negative affect as measured by PANAS-X6 weeks

Negative affect will be calculated by adding the values of the 25 negative items of the Positive and Negative Affect Schedule-X. Thus, the scale will range from 0 to 100 points with higher scores indicating worse mood.

Cognitive flexibility6 weeks

A task-switching test will be used to assess cognitive flexibility when switching between two predictable tasks requiring simple numerical decisions. The main outcome of interest is the average accuracy (0 to 100%).

Serum superoxide dismutase (SOD)6 weeks

Serum levels of superoxide dismutase (SOD) will be measured as an indicator of oxidative stress.

Serum total antioxidant capacity (TAC)6 weeks

The total antioxidant capacity (TAC) of serum will be measured to assess systemic antioxidant status.

Patient Health Questionnaire-9 (PHQ-9)6 weeks

A self-rated scale of depressive symptoms. The scale ranges from 0 to 27 points with higher scores indicating more severe depression.

Composite Quality of Life Index6 weeks

A 44-item composite index of quality of life derived by adding 11 facets of the WHOQOL-100 Questionnaire (General Health and Life Satisfaction, Pain and Discomfort, Energy and Fatigue, Sleep and Rest, Positive Feelings, Cognitive Function, Self-esteem, Negative Feelings, Activities of Daily Living, Work Capacity, and Personal Relationships). The scale ranges from 0 to 176 points with higher scores indicating better quality of life.

Positive affect as measured by PANAS-X6 weeks

Positive affect will be calculated by adding the values of the 21 positive items of the Positive and Negative Affect Schedule-X and the additional item "motivated". Thus, the scale will range from 0 to 88 points with higher scores indicating better mood.

Interleukin-6 (IL-6) in serum6 weeks

Serum levels of IL-6 will be analyzed using enzyme-linked immunosorbent assay (ELISA) as a marker of systemic inflammation.

Uric acid in serum6 weeks

Serum levels of uric acid will be measured using an automated chemistry analyzer.

Generalized Anxiety Disorder 7-item Scale (GAD-7)6 weeks

A brief self-rated scale of generalized anxiety. The scale ranges from 0 to 21 points with higher scores indicating more severe anxiety.

Perceived Stress Scale (PSS-10)6 weeks

A validated 10-item questionnaire to measure levels of perceived stress. The scale ranges from 0 to 40 points with higher scores indicating greater stress levels.

C-reactive protein (CRP) in serum6 weeks

Serum levels of CRP will be measured using an automated chemistry analyzer as a marker of systemic inflammation.

Trial Locations

Locations (1)

School of Psychology and Clinical Languages, University of Reading

🇬🇧

Reading, Berkshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath